| GTO ID | GTC3970 |
| Trial ID | NCT03852511 |
| Disease | Melanoma |
| Altered gene | E1 |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | NG-350A |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Multicentre, Open Label, Non-randomised First in Human Study of NG-350A (Monotherapy), and NG-350A With a Check Point Inhibitor in Patients With Metastatic or Advanced Epithelial Tumours |
| Year | 2019 |
| Country | United States |
| Company sponsor | Akamis Bio |
| Other ID(s) | NG-350A-01 |
| Vector information | |||||||
|
|||||||
| Cohort 1 | |||||||||
|
|||||||||